AstraZeneca share price rises on back of latest results

The latest surge was triggered by the Q4 and FY 2025 results which demonstrated strong commercial performance and pipeline delivery in what the company called a continuing catalyst-rich period.

AstraZeneca, now also quoted on the New York Stock Exchange, reports to UK stakeholders in dollars. Total revenue for the year was eight per cent ahead at $58,739 million, driven by Oncology, CVRM, R&I and Rare Disease and this growth was across all major geographic regions.

The core operating profit was up nine per cent while EPS increased 11 per cent to $9.16. A second interim dividend of $2.17 per share (159.5 pence, 19.49 SEK) was declared meaning that the total dividend declared for FY 2025 increased by three per cent to $3.20 per share.

AstraZeneca reported 16 positive Phase 3 readouts and 43 approvals in major regions in the last 12 months so there is massive headroom in terms of future pipeline and revenue growth.

CEO Pascal Soriot, said: "In 2025 we saw strong commercial performance across our therapy areas and excellent pipeline delivery. We announced the results of 16 positive Phase 3 studies during the year and now have 16 blockbuster medicines.

“The momentum across our company is continuing in 2026 and we are looking forward to the results of more than 20 Phase 3 trial readouts this year. We have more than 100 Phase 3 studies ongoing, including a substantial and growing number of trials of our transformative technologies which have the potential to revolutionise outcomes for patients and drive our growth well beyond 2030."